dolutegravir/lamivudine (Dovato)
Jump to navigation
Jump to search
Indications
Contraindications
Dosage
- once daily
Adverse effects
Laboratory
Notes
- FDA-approved April 2019
More general terms
Component of
Components
References
- ↑ FDA News Release. April 8, 2019 FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm635526.htm
- ↑ 2.0 2.1 Gandhi RT, Bedimo R, Hoy JF et al Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. 2022 Recommendations of the International Antiviral Society - USA Panel. JAMA. Published online December 1, 2022. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36454551 https://jamanetwork.com/journals/jama/fullarticle/2799240